-
Je něco špatně v tomto záznamu ?
Long-term experience with implantable treprostinil pumps in pulmonary arterial hypertension
V. Dytrych, J. Kuchar, D. Ambroz, J. Kunstyr, T. Grus, J. Lindner, A. Linhart, P. Jansa
Jazyk angličtina Země Slovensko
- Klíčová slova
- Treprostinil,
- MeSH
- epoprostenol * farmakologie terapeutické užití MeSH
- implantabilní infuzní pumpy MeSH
- injekce subkutánní metody škodlivé účinky MeSH
- kvalita života MeSH
- lidé MeSH
- natriuretický peptid typu B analýza krev MeSH
- plicní arteriální hypertenze * farmakoterapie terapie MeSH
- retrospektivní studie MeSH
- test chůzí metody MeSH
- Check Tag
- lidé MeSH
OBJECTIVES: To compare clinical parameters and quality of life in patients with pulmonary arterial hypertension (PAH) at the time of diagnosis, at the time of LenusPro pump implantation and during intravenous treptostinil treatment. METHODS: Seven patients with severe PAH treated with intravenous treptostinil via implantable LenusPro pumps were evaluated, including NYHA classification, six‐minute walking test, BNP and quality of life assessment using the EQ-5D-5L questionnaire before and after pump implantation. RESULTS: No significant changes were observed in NYHA class and six‐minute walking distance test. There was however a significant improvement in the quality of life and a decrease in BNP levels. The mean EQ-5D-5L index assessed during subcutaneous treptostinil treatment was significantly worse when compared to that assessed during its intravenous application (0.39 ± 0.24 vs 0.78 ± 0.28, p ˂ 0.05); the same is true about the pain/discomfort dimension. Complications occurred, namely one nonfatal pneumothorax, one nonfatal hemothorax, and one event of nonfatal treptostinil intoxication after refilling. CONCLUSIONS: In patients who do not tolerate subcutaneous treptostinil treatment, the use of the LenusPro implantable pump results in a significant improvement in quality of life with an acceptable safety profile (Tab. 2, Fig. 2, Ref. 19).
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024806
- 003
- CZ-PrNML
- 005
- 20250125200605.0
- 007
- cr|cn|
- 008
- 211012s2020 xo d fs 000 0|eng||
- 009
- AR
- 024 0_
- $a 10.4149/BLL_2020_057 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Dytrych, Vladimír $7 xx0080440 $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 245 10
- $a Long-term experience with implantable treprostinil pumps in pulmonary arterial hypertension / $c V. Dytrych, J. Kuchar, D. Ambroz, J. Kunstyr, T. Grus, J. Lindner, A. Linhart, P. Jansa
- 504 __
- $a Literatura
- 520 9_
- $a OBJECTIVES: To compare clinical parameters and quality of life in patients with pulmonary arterial hypertension (PAH) at the time of diagnosis, at the time of LenusPro pump implantation and during intravenous treptostinil treatment. METHODS: Seven patients with severe PAH treated with intravenous treptostinil via implantable LenusPro pumps were evaluated, including NYHA classification, six‐minute walking test, BNP and quality of life assessment using the EQ-5D-5L questionnaire before and after pump implantation. RESULTS: No significant changes were observed in NYHA class and six‐minute walking distance test. There was however a significant improvement in the quality of life and a decrease in BNP levels. The mean EQ-5D-5L index assessed during subcutaneous treptostinil treatment was significantly worse when compared to that assessed during its intravenous application (0.39 ± 0.24 vs 0.78 ± 0.28, p ˂ 0.05); the same is true about the pain/discomfort dimension. Complications occurred, namely one nonfatal pneumothorax, one nonfatal hemothorax, and one event of nonfatal treptostinil intoxication after refilling. CONCLUSIONS: In patients who do not tolerate subcutaneous treptostinil treatment, the use of the LenusPro implantable pump results in a significant improvement in quality of life with an acceptable safety profile (Tab. 2, Fig. 2, Ref. 19).
- 650 07
- $a lidé $7 D006801 $2 czmesh
- 650 17
- $a plicní arteriální hypertenze $x farmakoterapie $x terapie $7 D000081029 $2 czmesh
- 650 17
- $a epoprostenol $x farmakologie $x terapeutické užití $7 D011464 $2 czmesh
- 650 07
- $a implantabilní infuzní pumpy $7 D015918 $2 czmesh
- 650 07
- $a kvalita života $7 D011788 $2 czmesh
- 650 07
- $a test chůzí $x metody $7 D000070857 $2 czmesh
- 650 07
- $a natriuretický peptid typu B $x analýza $x krev $7 D020097 $2 czmesh
- 650 07
- $a retrospektivní studie $7 D012189 $2 czmesh
- 650 07
- $a injekce subkutánní $x metody $x škodlivé účinky $7 D007279 $2 czmesh
- 653 00
- $a Treprostinil
- 700 1_
- $a Kuchař, Jan $7 xx0252933 $u Department of Cardiology, Tabor Hospital, Inc., Czech Republic
- 700 1_
- $a Ambrož, David $7 xx0072987 $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Kunštýř, Jan $7 _AN033087 $u Department of Anesthesiology, Resuscitation and Intensive Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Grus, Tomáš, $d 1974- $7 xx0080427 $u 2nd Department of Surgery - Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Lindner, Jaroslav, $d 1957- $7 mzk2005269705 $u 2nd Department of Surgery - Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Linhart, Aleš, $d 1964- $7 mzk2003188958 $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 700 1_
- $a Jansa, Pavel, $d 1971- $7 jo2008427138 $u 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- 773 0_
- $t Bratislavské lekárske listy $x 0006-9248 $g Roč. 121, č. 5 (2020), s. 358-361 $w MED00000845
- 856 41
- $u http://www.elis.sk/download_file.php?product_id=6680&session_id=vqcv5omiqd8n4relp2g02i6ia2 $y plný text volně přístupný
- 910 __
- $a ABA008 $b online $c 1067 $y p $z 0
- 990 __
- $a 20211012144111 $b ABA008
- 991 __
- $a 20250125200611 $b ABA008
- 999 __
- $a ok $b bmc $g 1707783 $s 1145313
- BAS __
- $a 3 $a 4
- BMC __
- $a 2020 $b 121 $c 5 $d 358-361 $i 0006-9248 $m Bratislavské lekárske listy $x MED00000845
- LZP __
- $c NLK192 $d 20250125 $a NLK 2021-43/kv
